Seaport Therapeutics Q2 FY26 net loss widens to $62.6 million; R&D expenses rise to $24.62 millionPUBT·7 hours agoSPTX-0.54%
Seaport Therapeutics director Robert J. Hombach trust buys 13,000 shares worth $235,768PUBT·Jun 24 at 05:05 AMSPTX-0.54%
3 Best Stocks to Buy Today, 6/9/2026, According to Top AnalystsTip Ranks·Jun 9 at 10:29 AMEVLV+2.53%SPTX-0.54%
Seaport Therapeutics shares are trading higher after the company announced data from the multiple-ascending dose portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo in healthy volunteers.benzinga_article·Jun 9 at 09:55 AMSPTX-0.54%
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress | SPTX Stock NewsStockTitan·Jun 7 at 10:05 PMSPTX-0.54%
General Atlantic Discloses Investment at Seaport Therapeutics with 11.5% StakeTradingView·May 11 at 06:56 PMSPTX-0.54%
